Tags

Type your tag names separated by a space and hit enter

Growth hormone response to catecholamine depletion in unmedicated, remitted subjects with major depressive disorder and healthy controls.
J Clin Psychopharmacol 2013; 33(5):621-6JC

Abstract

We investigated whether the human growth hormone (HGH) response to catecholamine depletion differs between fully remitted patients with major depressive disorder and healthy control subjects. Fourteen unmedicated subjects with remitted major depressive disorder (RMDD) and 11 healthy control subjects underwent catecholamine depletion with oral α-methylparatyrosine (AMPT) in a randomized, placebo-controlled, double-blind crossover study. The main outcome measure was the serum level of HGH. The diagnosis × drug interaction for HGH serum concentration was significant (F₁,₂₃ = 7.66, P < 0.02). This interaction was attributable to the HGH level increasing after AMPT administration in the RMDD subjects but not in the healthy subjects. In the RMDD sample, the AMPT-induced increase in HGH concentration correlated inversely with AMPT-induced anxiety symptoms as assessed using the Beck Anxiety Inventory (r = -0.63, P < 0.02). There was a trend toward an inverse correlation of the AMPT-induced HGH concentration changes with AMPT-induced depressive symptoms as measured by the BDI (r = -0.53, P = 0.05). Following catecholamine depletion, the RMDD subjects were differentiated from control subjects by their HGH responses. This finding, together with the negative correlation between HGH response and AMPT-induced anxiety symptoms in RMDD subjects, suggests that AMPT administration results in a deeper nadir in central catecholaminergic transmission, as reflected by a greater disinhibition of HGH secretion, in RMDD subjects versus control subjects.

Authors+Show Affiliations

University Hospital of Psychiatry, University of Bern, Bern, Switzerland.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23963054

Citation

Homan, Philipp, et al. "Growth Hormone Response to Catecholamine Depletion in Unmedicated, Remitted Subjects With Major Depressive Disorder and Healthy Controls." Journal of Clinical Psychopharmacology, vol. 33, no. 5, 2013, pp. 621-6.
Homan P, Drevets WC, Hasler G. Growth hormone response to catecholamine depletion in unmedicated, remitted subjects with major depressive disorder and healthy controls. J Clin Psychopharmacol. 2013;33(5):621-6.
Homan, P., Drevets, W. C., & Hasler, G. (2013). Growth hormone response to catecholamine depletion in unmedicated, remitted subjects with major depressive disorder and healthy controls. Journal of Clinical Psychopharmacology, 33(5), pp. 621-6. doi:10.1097/JCP.0b013e31829a8284.
Homan P, Drevets WC, Hasler G. Growth Hormone Response to Catecholamine Depletion in Unmedicated, Remitted Subjects With Major Depressive Disorder and Healthy Controls. J Clin Psychopharmacol. 2013;33(5):621-6. PubMed PMID: 23963054.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Growth hormone response to catecholamine depletion in unmedicated, remitted subjects with major depressive disorder and healthy controls. AU - Homan,Philipp, AU - Drevets,Wayne C, AU - Hasler,Gregor, PY - 2013/8/22/entrez PY - 2013/8/22/pubmed PY - 2014/4/2/medline SP - 621 EP - 6 JF - Journal of clinical psychopharmacology JO - J Clin Psychopharmacol VL - 33 IS - 5 N2 - We investigated whether the human growth hormone (HGH) response to catecholamine depletion differs between fully remitted patients with major depressive disorder and healthy control subjects. Fourteen unmedicated subjects with remitted major depressive disorder (RMDD) and 11 healthy control subjects underwent catecholamine depletion with oral α-methylparatyrosine (AMPT) in a randomized, placebo-controlled, double-blind crossover study. The main outcome measure was the serum level of HGH. The diagnosis × drug interaction for HGH serum concentration was significant (F₁,₂₃ = 7.66, P < 0.02). This interaction was attributable to the HGH level increasing after AMPT administration in the RMDD subjects but not in the healthy subjects. In the RMDD sample, the AMPT-induced increase in HGH concentration correlated inversely with AMPT-induced anxiety symptoms as assessed using the Beck Anxiety Inventory (r = -0.63, P < 0.02). There was a trend toward an inverse correlation of the AMPT-induced HGH concentration changes with AMPT-induced depressive symptoms as measured by the BDI (r = -0.53, P = 0.05). Following catecholamine depletion, the RMDD subjects were differentiated from control subjects by their HGH responses. This finding, together with the negative correlation between HGH response and AMPT-induced anxiety symptoms in RMDD subjects, suggests that AMPT administration results in a deeper nadir in central catecholaminergic transmission, as reflected by a greater disinhibition of HGH secretion, in RMDD subjects versus control subjects. SN - 1533-712X UR - https://www.unboundmedicine.com/medline/citation/23963054/Growth_hormone_response_to_catecholamine_depletion_in_unmedicated_remitted_subjects_with_major_depressive_disorder_and_healthy_controls_ L2 - http://Insights.ovid.com/pubmed?pmid=23963054 DB - PRIME DP - Unbound Medicine ER -